Progress Against Kidney Cancer. 1970–1979 Progress Against Kidney Cancer 1970–1979 1977: Removing just part of the cancerous kidney is proven safe and.

Slides:

Advertisements

Similar presentations

Clinical Cancer Advances 2012

Advertisements

Spanish Oncology GenitoUrinary Group

Major Cancer Milestones

Progress Against Breast Cancer

Progress Against Prostate Cancer. 1970–1979 Progress Against Prostate Cancer 1970–1979 Early 1970s: Radioactive ''seeds'' proven effective for prostate.

Progress Against Lung Cancer. 1970–1979 Progress Against Lung Cancer 1970–1979 Mid-1970s: Chemotherapy combinations prove effective in small cell lung.

Progress Against Stomach Cancer. 1980–1989 Progress Against Stomach Cancer 1980– : Combination chemotherapy improves outcomes for advanced stomach.

Progress Against Lymphoma. 1970–1979 Progress Against Lymphoma 1970– : FDA approves doxorubicin, a vital part of combination chemotherapy.

Progress Against Bladder Cancer. Pre-1970 Progress Against Bladder Cancer Pre : Tool offers view inside bladder for first time.

Progress Against Ovarian Cancer. 1970–1979 Progress Against Ovarian Cancer 1970– : First effective combination chemotherapy regimen for ovarian.

Progress Against Testicular Cancer. 1970–1979 Progress Against Testicular Cancer 1970– : Two new drugs produce first complete remissions in advanced.

Progress Against Cervical Cancer. 1980–1989 Progress Against Cervical Cancer 1980– –1984: HPV virus is discovered to cause cervical cancer.

Progress Against Head and Neck Cancer. 1970–1979.

Progress Against Melanoma. 1970–1979 Progress Against Melanoma 1970– : Hereditary syndrome linked to increased melanoma risk.

Progress Against Leukemia. 1970–1979 Progress Against Leukemia 1970– : FDA approves doxorubicin.

Progress Against Pancreatic Cancer. 1970–1979 Progress Against Pancreatic Cancer 1970– s: Tobacco use found to cause pancreatic cancer.

Progress Against Liver Cancer. 1970–1979 Progress Against Liver Cancer 1970– : First study finds chemotherapy effective for liver cancer.

TABLE OF CONTENTS CHAPTER 1.0: Trends in the Overall Health Care Market Chart 1.1: Total National Health Expenditures, 1980 – 2005 Chart 1.2: Percent Change.

TABLE OF CONTENTS CHAPTER 4.0: Trends in Hospital Financing Chart 4.1: Percentage of Hospitals with Negative Total and Operating Margins, 1995 – 2009.

Presenter Name(s) Issue date National Student.

First cases of AIDS identified.

How Universal will Universal Access be in Europe by 2010? Eddy Beck Evaluation Department UNAIDS, Geneva

Through the years… JUNIATA COLLEGE FIELD HOCKEY. SeasonCoachRecord 1973Unknown Jo Reilly Alexa Fultz Alexa Fultz Nancy Harden-Latimore4-4-1.

CTOS Herman Suit CTOS Special Award Lecture November 2005 Professor Herman D Suit Massachusetts General Hospital Dept. of Radiation Oncology Boston.

From Delft into Almere Prof.dr.ir.Taeke M. de Jong.

Don Zoellner The Northern Institute Do not pass go, do not collect $200 THE PRIORITY GIVEN TO VOCATIONAL EDUCATION RESEARCH AND POLICY.

Trends in incidence and mortality, England 1989 to 2010.

Regional Perspectives on Renal Cell Carcinoma Mohamed Abdulla M.D. Professor of Clinical Oncology Cairo University AfME. September 17 th 2010W:

Hybrid Tumor Vaccines David L. Liu, MD, PhD Professor of Surgery and Oncology Tumor Immunotherapy Division RedSun Institute 242 Dorchester Street, Boston,

MS&E 220 Project Yuan Xiang Chew, Elizabeth A Hastings, Morris Jinhui Zhang Probabilistic Analysis of Cervical Cancer Screening and Vaccination.

Cancer Clinical Trials:

Cancer Clinical Trials: The Way We Make Progress Against Cancer.

Myths and Facts About Cancer Clinical Trials. Copyright ENACCT, 2007 It’s a treatment of “last resort!” They treat you like a “guinea pig ” No one benefits.

KIDNEY CANCER By: Kendall Whitney. WHAT IS KIDNEY CANCER?  Cancer that forms in tissues of the kidneys. Kidney cancer includes cancer that forms in the.

Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.

Immunotherapy in Renal Cell Ca F.Ghadiri M.D Radiation Oncologist.

Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.

ACRIN 6671/GOG 0233 Consent for Research Study A study for Women with Advanced Cervical Cancer: Learning whether a PET/CT scan using an imaging agent called.

New Developments in Cancer Treatment Dulcinea Quintana, MD.

BME 301 Lecture Twenty-Two. How are health care technologies managed? Examples: MRI Laparoscopic cholecystectomy Vitamin C treatment for scurvy Research.

Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.

The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena

Cancer cell–selective in vivo Treating cancer with light activated, antibody-dye conjugates by Amol Kapoor and Teddy Leithead Makoto Mitsunaga, Mikako.

Immunotherapy Sara Engh & Tenzin Yiga. Role of the Immune system ➔ Defends against pathogens such as bacteria, fungi, and viruses that enter the body.

Renal cell cancer: Integrating novel agents into a therapeutic algorithm Robert Dreicer, M.D., FACP Chairman Department of Solid Tumor Oncology Taussig.

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

What is gene therapy? Do now: In your own words,

Pancreatic Cancer in the US – 12/2015 TIMOTHY PAULUS - TESTIMONY 1/20/2016.

C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

Kidney Cancer Like other cancers, kidney or “renal cell” cancer has a family history in 4% of the cases. Familial kidney cancers, like sporadic cases,

CANCER THERAPY  Surgery  Radiation Therapy  Chemotherapy  Stem Cell Transplant  Immunotherapy  Targeted Therapy  Hormone Therapy  Precision Medicine.

The Use of Milnacipran in Treating Fibromyalgia. MilnacipranMilnacipran, also known as milnacipran hydrochloride or Savella, helps to alleviate the pain.

MESOTHELIOMA PROGNOSIS A mesothelioma prognosis reflects how certain factors may impact your life expectancy and affect your chances of recovery. The average.

Clinical and Research Updates in Gynecologic Oncology

Bijoy Telivala, MD Advances in Immunotherapy Bijoy Telivala, MD

PHEN Clinical Trials Rally

COMPLICATIONS OF IMMUNOTHERAPY IN THE HOSPITALIZED PATIENT Vivek Batra MD, Emma Weaver MD Division of Medical Oncology, Thomas Jefferson University, Philadelphia.

The Immune System. The Immune System Adaptive Immune Response.

Discussion Outline Cells of the Immune System.

Progression After Cancer Immunotherapy in Advanced NSCLC

Introduction to Checkpoint Inhibitors

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.

Tumor Immunity ——卓越一班二组——. Tumor Immunity ——卓越一班二组——

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Targeted Therapies for Hepatocellular Carcinoma

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Presentation transcript:

Progress Against Kidney Cancer

1970–1979

Progress Against Kidney Cancer 1970– : Removing just part of the cancerous kidney is proven safe and effective

Progress Against Kidney Cancer 1980–1989

Progress Against Kidney Cancer 1980– : Immunotherapy benefits patients with advanced renal cell carcinoma

Progress Against Kidney Cancer 1990–1999

Progress Against Kidney Cancer 1990– : Introduction of laparoscopic surgery minimizes pain, recovery time

Progress Against Kidney Cancer 1990– : First immunotherapy approved for kidney cancer

Progress Against Kidney Cancer 1990– –1997: New treatment techniques introduced for small renal tumors

Progress Against Kidney Cancer 2000–Present

Progress Against Kidney Cancer 2000–Present 2000: Combination of kidney removal and immunotherapy extends life

Progress Against Kidney Cancer 2000–Present 2005: First FDA approval of a targeted drug for kidney cancer

Progress Against Kidney Cancer 2000–Present 2006–2007: Two new targeted drugs are proven effective in major trials; FDA approvals follow

Progress Against Kidney Cancer 2000–Present 2009: Everolimus approved for renal cell carcinoma if other drugs fail 2009: Bevacizumab approved for renal cancer after multiple studies confirm benefit 2009: Pazopanib approved for advanced kidney cancer

Progress Against Kidney Cancer 2000–Present 2011: FDA approves axitinib for persistent kidney cancer

Progress Against Kidney Cancer Five-Year Survival Source: National Cancer Institute

Progress Against Kidney Cancer Mortality Source: National Cancer Institute

Progress Against Kidney Cancer New Cases Source: National Cancer Institute

Visit CancerProgress.Net for an interactive timeline of progress against a range of common cancers CancerProgress.Net is a project of the American Society of Clinical Oncology, which represents nearly 30,000 physicians who treat people with cancer and research new cures